Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cyclocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclocreatine SCHEMBL446535 | 0.92 | TSHR (0.35) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL7935371 | 0.88 | CYP2D6 (0.39) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL450343 | 0.88 | CYP2D6 (0.39) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL11796002 | 0.87 | CYP2D6 (0.38) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL1980714 | 0.85 | CYP2D6 (0.37) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL1981687 | 0.81 | INMT (0.40) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL448277 | 0.78 | ACE (0.39) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL1980609 | 0.74 | SMN1; SMN2 (0.44) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14537232 | 0.73 | BDKRB2 (0.33) | TSHRKMT2A | |
| SCHEMBL19719147 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2327404-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | Avicena Group, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090005450-A1 | Use of creatine compounds for the treatment of eye disorders | AVICENA GROUP, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20020049253-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1198230-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | Avicena Group, Inc. (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001055719-A2 | DIAGNOSTIC KIT FOR DETECTING CREATINE LEVELS | FAL DIAGNOSTICS (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6242491-B1 | ADMINISTERING CREATINE PHOSPHATE FOR WRINKLE, AGING, AND SOLAR RADIATION RESISTANCE AND AS FREE RADICAL SCAVENGER | LIBRARY PHARMA, INC. | 2001-06-05 | — | — | US | disclosed |
| EP-1065931-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | Avicena Group, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2001000212-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE PREVENTION AND TREATMENT OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES | AVICENA GROUP, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000203-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-1999051097-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | AVICENA GROUP, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0804183-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENDA GROUP, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996014063-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | CKMT1A; CKMT1B, CRAT, LRAT | TSHR 4507/4885POLB 1269/4885CYP2D6 872/4885 |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | CKMT1A; CKMT1B, PC, PCK2 | TSHR 2432/4885POLB 611/4885CYP2D6 3294/4885 |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20020049253-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20090005450-A1 | Use of creatine compounds for the treatment of eye disorders | ALDH1A2, RXFP1, RBP4 | TSHR 1436/4885POLB 3435/4885CYP2D6 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.